Abstract
This study analyzed the US Food and Drug Administration–listed patents on glucagon-like peptide 1 (GLP-1) receptor agonists to determine their claim characteristics and the potential barriers they pose to generic entry.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have